Glycopeptide drugs

Medicinal Chemistry

ISSN: 2161-0444

Open Access

Glycopeptide drugs

5th International Conference on Medicinal Chemistry & Computer Aided Drug Designing and Drug Delivery

December 05-07, 2016 Phoenix, USA

Robin Polt

University of Arizona, USA

Scientific Tracks Abstracts: Med chem

Abstract :

Parkinsonâ??s disease (PD) is the 2nd most common neurodegenerative disorder, affecting over 1 million people in the US. Parkinsonâ??s disease causes difficulties with movements such as walking, writing and speaking that occur because of deficiencies of the chemical dopamine in the brain. Current therapies for PD only treat the symptoms and do not reverse underlying disease processes that cause dopamine-producing brain cells to die. This situation has led to widespread interest in new strategies of neuroprotection or neurorestoration. The mostpromising approaches to modifying the disease process in the laboratory have relied on natural brain chemicals known as â??growth factorsâ?. Several growth factors have demonstrated the ability to reverse the disease process in animal models of PD. A few of these growth factors have shown sufficient promise that they have been tested in clinical trials in humans with PD. One promising approach is offered by the peptide â??secretinsâ? vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) which plays important roles in neuronal survival, neuroprotection, inflammation and immunomodulation. PACAP seems to be protective against the loss of dopamine-producing brain cells in rodent model of Parkinsonâ??s, but only after being injected directly into the brain. The proposed glycopeptides are surfactants, chemically speaking, and have extended half-lives in vivo and unlike their peptide counterparts, these molecules can efficiently cross the blood-brain barrier (BBB). We have developed a new technology platform to develop glycopeptide analogues that show increased stability. We will synthesize a series of novel glycopeptides based on PACAP and VIP to screen their efficacy at PAC1, VPAC1 and VPAC2 receptors expressed in CHO reporter cells and test the most promising compounds in animal models of Parkinsonâ??s disease. We will be assisted greatly in this endeavor by micro-dialysis data that will allow us to quantify brain levels of the drug over time, and direct measurements of drug stability in vivo. This is accomplished by multiple collision-induced fragmentation mass spectroscopy (MSn). In this way we hope to produce one or more drug candidates for further study, ultimately leading to clinical application.

Biography :


Google Scholar citation report
Citations: 6627

Medicinal Chemistry received 6627 citations as per Google Scholar report

Medicinal Chemistry peer review process verified at publons

Indexed In

arrow_upward arrow_upward